Standard BioTools Inc. (LAB) Financial Ratios
20 years of historical data (2006–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.90
↓-52% vs avg
5yr avg: 1.87
30Y Low1.2·High10.0
ROE
↑
-16.7%
↓+98% vs avg
5yr avg: -762.3%
30Y Low-144%·High-16%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LAB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Standard BioTools Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $390M | $488M | $617M | $175M | $92M | $297M | $432M | $232M | $342M | $194M | $211M |
| Enterprise Value | $303M | $401M | $483M | $221M | $113M | $380M | $459M | $271M | $418M | $331M | $371M |
| P/E Ratio → | -5.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.57 | 5.72 | 3.54 | 1.65 | 0.94 | 2.28 | 3.13 | 1.98 | 3.03 | 1.91 | 2.02 |
| P/B Ratio | 0.90 | 1.15 | 1.31 | — | — | 3.14 | 3.11 | 1.51 | 4.74 | 6.28 | 3.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LAB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.70 | 2.77 | 2.08 | 1.15 | 2.91 | 3.32 | 2.31 | 3.70 | 3.25 | 3.55 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
LAB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Standard BioTools Inc. earns an operating margin of -109.3%. Operating margins have compressed from -72.0% to -109.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -16.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.9% | 49.9% | 48.3% | 47.4% | 37.8% | 53.1% | 60.3% | 54.8% | 54.6% | 51.0% | 55.9% |
| Operating Margin | -109.3% | -109.3% | -100.5% | -72.0% | -118.6% | -51.7% | -36.9% | -44.2% | -42.6% | -57.3% | -70.1% |
| Net Profit Margin | -87.8% | -87.8% | -79.6% | -70.2% | -194.1% | -45.4% | -38.4% | -55.3% | -52.2% | -59.4% | -72.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.7% | -16.7% | -85.8% | — | -2895.8% | -50.7% | -36.2% | -57.4% | -114.5% | -143.8% | -90.4% |
| ROA | -12.7% | -12.7% | -29.7% | -20.9% | -57.1% | -19.7% | -18.0% | -22.8% | -20.0% | -20.4% | -22.4% |
| ROIC | -20.7% | -20.7% | -111.2% | — | -148.1% | -29.4% | -21.4% | -22.8% | -22.8% | -23.0% | -22.2% |
| ROCE | -18.6% | -18.6% | -46.1% | -27.3% | -40.6% | -27.2% | -20.3% | -20.8% | -18.5% | -22.0% | -23.7% |
LAB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $118M exceeds total debt of $31M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.07 | — | — | 1.18 | 0.69 | 0.39 | 2.39 | 6.31 | 3.66 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.28 | — | — | 0.88 | 0.19 | 0.25 | 1.06 | 4.43 | 3.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3718.31 | -3718.31 | -40.71 | -15.25 | -43.55 | -15.65 | -14.15 | -14.59 | -3.42 | -9.95 | -12.78 |
Net cash position: cash ($118M) exceeds total debt ($31M)
LAB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Standard BioTools Inc.'s current ratio of 4.19x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.45x to 4.19x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.19 | 4.19 | 5.70 | 1.45 | 4.81 | 1.45 | 2.17 | 2.93 | 3.38 | 2.83 | 3.28 |
| Quick Ratio | 4.01 | 4.01 | 5.09 | 1.26 | 4.31 | 1.03 | 1.81 | 2.50 | 3.04 | 2.38 | 2.60 |
| Cash Ratio | 1.73 | 1.73 | 4.44 | 1.05 | 3.82 | 0.57 | 1.26 | 1.79 | 2.54 | 1.89 | 2.01 |
| Asset Turnover | — | 0.15 | 0.28 | 0.33 | 0.25 | 0.47 | 0.43 | 0.44 | 0.37 | 0.35 | 0.34 |
| Inventory Turnover | 2.14 | 2.14 | 2.21 | 2.72 | 2.84 | 2.94 | 2.78 | 3.81 | 3.95 | 3.31 | 2.29 |
| Days Sales Outstanding | — | 57.45 | 70.32 | 67.48 | 64.39 | 51.21 | 67.17 | 59.09 | 53.80 | 53.89 | 51.06 |
LAB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Standard BioTools Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 6.6% | 3.1% | 0.8% | 0.6% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 6.6% | 3.1% | 0.8% | 0.6% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% |
| Shares Outstanding | — | $382M | $353M | $79M | $78M | $76M | $72M | $67M | $40M | $33M | $29M |
Peer Comparison
Compare LAB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LABYou | $390M | -5.0 | — | — | 49.9% | -109.3% | -16.7% | -20.7% | — |
 AZTA | $855M | -15.2 | 13.8 | 22.3 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 SEER | $105M | -1.4 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.9 | 18.2 | 23.6 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $7B | 9.2 | 16.7 | 18.5 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 BRKR | $7B | -291.5 | 18.4 | 153.7 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
See LAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LAB vs AZTA
Side-by-side business, growth, and profitability comparison vs Azenta, Inc..
Start ComparisonLAB — Frequently Asked Questions
Quick answers to the most common questions about buying LAB stock.
What is Standard BioTools Inc.'s P/E ratio?
Standard BioTools Inc.'s current P/E ratio is -5.0x. This places it at the 50th percentile of its historical range.
What is Standard BioTools Inc.'s ROE?
Standard BioTools Inc.'s return on equity (ROE) is -16.7%. The historical average is -58.3%.
Is LAB stock overvalued?
Based on historical data, Standard BioTools Inc. is trading at a P/E of -5.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Standard BioTools Inc.'s profit margins?
Standard BioTools Inc. has 49.9% gross margin and -109.3% operating margin.